【Significant Favorable News】Poly Pharmaceuticals contributes to the significant achievements of CDMO's innovative immunotherapy drugs, taking a step closer to full commercialization !

Remarkable results achieved on Innovative Immunotherapy Drugs Strengthen the cooperation between Pol...

View details

Hainan Poly Pharm.Co., Ltd in the 2024 DCAT Week

Hainan Poly Pharm.Co., Ltd will be participating in the 2024 DCAT Week (Drug, Chemical & Associa...

View details

【​INVITATION】CPHI2023 Booth No. : 2P29 --POLY PHARM

CPHI2023 will be held in 24th~26th Oct. 2023 in Barcelona, SpainHainan Poly Pharm Co.,Lted will ...

View details

Zhejiang Poly Pharmaceutical's Eye Drop Workshop Complies with Chinese, American, and European GMP Requirements - Open to Domestic and International CDMO/CMO Collaborations

Zhejiang Poly Pharmaceutical is a wholly-owned subsidiary of Hainan Poly Pharmaceutical (stock code:...

View details

Anhui Poly Pharmaceutical's Magnesium Hydroxide API Approved for Market, with a Yearly Production Capacity of Up to 200 Tons!

Anhui Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Poly") recently rec...

View details

Poly Pharmaceutical Obtains Market Approval for Azithromycin Injection in Israel, Further Securing Antibiotic Supply

Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Poly Pharmaceutical") recently ...

View details

Hainan Poly Pharmaceuticals’ Injection and Raw Material Workshops Receive US FDA Certification Again!

From June 22, 2023, to June 30, 2023, Poly Pharmaceuticals underwent an on-site inspection by the Un...

View details

Poly Pharmaceuticals’ High-End Pediatric Medicine Open the US Market, Zhejiang Poly's Azithromycin Dry Powder Suspension (Precision Dosing) Becomes the First Chinese Product to Receive FDA Approval!

In the United States, stringent requirements for precision dosing of pediatric medications are in pl...

View details